UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 29, 2007

Biogen Idec Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

0-19311 (Commission File Number)		33-0112644 (IRS Employer Identification No.)

14 Cambridge Center, Cambridge, Massachusetts (Address of Principal Executive Offices)		02142 (Zip Code)

(617) 679-2000
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

ITEM 5.02.   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

       On June 29, 2007, Biogen Idec Inc. announced the resignation of Executive Vice President, Finance and Chief Financial Officer Peter Kellogg. A copy of the press release is attached hereto as Exhibit 99.1 and its contents are incorporated herein by reference.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.

(d)   Exhibits

Exhibit No.		Description
99.1		Press release dated June 29, 2007

SIGNATURES

       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 29, 2007

Exhibit 99.1

For More Information Contact:
Biogen Idec Media Contact:
Tim Hunt, Vice President
Public Affairs
(617) 914-6524

Investment Community Contact:
Elizabeth Woo, Vice President
Investor Relations
(617) 679-2812

BIOGEN IDEC ANNOUNCES MANAGEMENT CHANGE

Cambridge, MA (June 29, 2007) — Biogen Idec (NASDAQ: BIIB) announced today that Peter Kellogg, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to become CFO at Merck & Co., Inc.

“I want to thank Peter for his seven years of distinguished service to the organization,” stated James C. Mullen, Biogen Idec’s President and Chief Executive Officer. “Peter is a world-class financial executive who helped Biogen Idec grow our core therapeutic areas, execute several significant deals, and expand our global footprint. We wish him all the best with his new assignment at Merck.”

Mr. Kellogg will leave Biogen Idec on August 10. The Company will announce its plans regarding the CFO position over the next several weeks.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

###